Associated British Foods announced a review of the structure of the group alongside its full-year financial results.
In October 2025, Terns Pharmaceuticals announced strongly positive Phase 1 data for TERN-701 in chronic myeloid leukemia, with a 75% major molecular response rate by 24 weeks and no dose-limiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback